Susceptibility of pseudomonas aeruginosa to fluoroquinolones following four years of use in a tertiary care hospital

Journal of Antimicrobial Chemotherapy

Volumn 30, Issue 2, 1992, Pages 149-152

  Shalit, Itamar ^a   Haas, Hava ^a   Berger, A ^b  

^a Infectious Diseases Unit   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; OFLOXACIN; PEFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CROSS RESISTANCE; HOSPITAL INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; WOUNDS AND INJURIES;

EID: 0026744004     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/30.2.149     Document Type: Article

References (11)

1. Barry, A. L., Fass, R. J., Anhalt, J. P., Neu, H. C., Thomsbcrry, C., Tilton, R. C. et al. (1985).Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-/ig disks. Journal of Clinical Microbiology 21, 880-3.
2. Chamberland, S., Bayer, A. S., Schollaardt, T., Wong, S. A. and Bryan, L. E. (1989). Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrobial Agents and Chemotherapy 33, 624-34.
3. Fuchs, P. C., Barry, A. L., Jones, R. N. and Thomsbcrry, C. (1986). Tentative disk diffusion susceptibility interpretive criteria forpefloxacin. Journal of Clinical Microbiology 24,448-50.
4. Fuchs, P. C., Jones, R. N., Barry, A. L., Gavan, T. C. and the Collaborative Antimicrobial Susceptibility Test Group. (1989). Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria. Journal of Clinical Microbiolog 27, 49-52.
5. Gutmann, L., Williamson, R., Moreau, N., Kitzis, M. D., Collatz, E., Acar, J. F. et al. (1985). Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacler, and Serratia. Journal of Infectious Diseases 151, 501-7.
6. Kresken, M. and Wiedemann, B. (1988). Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrobial Agents and Chemotherapy 32, 1285-8.
7. Michea-Hamzehpour, M., Lucain, C. and Pechere, J.-C. (1991). Resistance to pefloxacin in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 35, 512-8.
8. Muder, R. R., Brennen, C., Goetz, A. M., Wagener, M. M. and Rihs, J. D. (1991). Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among Gram-negative isolates in a Veterans Affairs medical center. Antimicrobial Agents and Chemotherapy 35, 256-8.
9. Sanders, C. C., Sanders, W. E., Goering, R. V. and Werner, V. (1984). Selection of multiple antibiotic resistance by quinolones, 0-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrobial Agents and Chemotherapy 26, 797-801.
10. Shalit, I., Berger, S. A., Gorea, A. and Frimerman, H. (1989). Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrobial Agents and Chemotherapy 33, 593-4.
11. Shalit, I., Dan, M., Gutman, R., Gorea, A. and Berger, S. A. (1990). Cross resistance to ciprofloxacin and other antimicrobial agents among clinical isolates of Acinetobacter calcoaceticus biovar anitratus. Antimicrobial Agents and Chemotherapy 34, 494-5.